Н.Е. Кушлинский - д.м.н., профессор, чл.-корр. РАН, зав. лабораторией клинической биохимии, Российский онкологический научный центр им. Н.Н. Блохина РАМН (Москва). E-mail: biochimia@mtu-net.ru А.А. Зуев - соискатель, кафедра клинической биохимии и лабораторной диагностики ФПДО, Московский государственный медико-стоматологический университет им. А.И. Евдокимова Ю.С. Тимофеев - врач клинической лабораторной диагностики, лаборатория клинической биохимии, Российский онкологический научный центр им. Н.Н. Блохина РАМН (Москва)

Дано описание патологической активности системы при таких состояниях, как рак молочной железы, рак простаты, множественная миелома, плоскоклеточный рак, болезнь Ходжкина, при метастазах в кости при раке легких и при других злокачественных заболеваниях. В литературе имеются данные о вовлеченности системы RANK/RANKL/OPG в патогенез опухолей костей (гигантоклеточная опухоль кости, хондробластома). Получены экспериментальные данные, согласно которым ингибиторы RANKL способны играть роль в уменьшении очагов опухоль-индуцированного поражения костей при множественной миеломе, раке молочной железы, простаты и легких. Приведены данные клинических исследований эффективности препаратов, направленных на систему RANK/RANKL/OPG.

1. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis // Endocrine Reviews. 2000. V. 21. № 2. P. 115 - 137.
2. Manolagas S.C., Jilka R.L. Mechanisms of disease: bone marrow, cytokines, and bone remodeling-emerging insights into the pathophysiology of osteoporosis // N. Engl. J. Med. 1995. V. 332. № 5. P. 305 - 311.
3. Raggatt L.J., Partridge N.C. Cellular and molecular mechanisms of bone remodeling // J. Biol. Chem. 2010. V. 285. Suppl. 33. P. 25103 - 25108.
4. Komori T. Regulation of osteoblast differentiation by RUNX2 // Osteoimmunology. 2010. V. 658. Suppl. 1. P. 43 - 49.
5. Datta H.K., Ng W.F., Walker J.A. et al. The cell biology of bone metabolism // J. Clin. Pathol. 2008. V. 61. Suppl. 5. P. 577 - 587.
6. Crockett J.C., Rogers M.J., Coxon F.P. et al. Bone remodeling at a glance // J. Cell Sci. 2011. V. 124. Suppl. 7. P. 991 - 998.
7. Sagalovsky S., Schonert M. RANKL-RANK-OPG system and bone remodeling: a new approach to the treatment of osteoporosis // Clin. Exp. Pathol. 2011. V. 10. Suppl. 2. P. 146 ? 153.
8. Teitelbaum S.L. Bone resorption by osteoclasts // Science. 2000. V. 289. № 5484. P. 1504 - 1508.
9. Hofbauer L., Rachner T. Die rolle des RANKL-RANK-OPG-Signalwegs in Knochenstoffwechsel // Forbildung Osteoiogie. 2010. V. 3. Suppl. 8. P. 118 ? 121.
10. Choi H.J., Park Y.R., Nepal M. et al. Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-κB signaling pathways // Eur. J. Pharmacol. 2010. V. 636. № 1-3. P. 28 - 35.
11. Maruyama T., Fukushima H., Nakao K. et al. Processing of the NF-κB2 precursor p100 to p52 is critical for RANKL-induced osteoclast differentiation // J. Bone Miner. Res. 2010. V. 25. № 5. P. 1058 - 1067.
12. Vaira S., Alhawagri M., Anwisye I., Kitaura H., Faccio R., Novack D.V. RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice // J. Clin. Invest. 2008. V. 118. № 6. P. 2088 - 2097.
13. Zhao Q., Wang X., Liu Y. et al. NFATc1: functions in osteoblasts // Int. J. Biochem. Cell Biol. 2009. V. 42. Suppl. 5. P. 576 - 579.
14. Rucci N. Molecular biology of bone remodeling // Clin. Cases Miner. Bone Metab. 2008. V. 5. Suppl. 1. P. 49 - 56.
15. Wilson S.R., Petersilso C., Saftig P., Bromme D. Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption // J. Biol. Chem. 2009. V. 284. Suppl. 4. P. 2584 - 2592.
16. Kong Y., Yoshida H., Sarosi I. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis // Nature. 1999. V. 397. № 6717. P. 315 - 323.
17. Kong Y.Y., Boyle W.J., Penninger J.M. Osteoprotegerin ligand: a common link between osteoclastogenesis, lymph node formation and lymphocyte development // Immunol. Cell Biol. 1999. V. 77. № 2. P. 188 - 193.
18. Bucay N., Sarosi I., Dunstan C.R. et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification // Genes and Development. 1998. V. 12. № 9. P. 1260 - 1268.
19. Whyte M.P., Obrecht S.E., Finnegan P.M. et al. Osteoprotegerin deficiency and juvenile Paget's disease // N. Engl. J. Med. 2001. V. 347. № 3. P. 175 - 184.
20. Whyte M.P., Singhellakis P.N., Petersen M.B., Davies M., Totty W.G., Mumm S. Juvenile Paget's disease: the second reported, oldest patient is homozygous for the TNFRSF11B "Balkan" mutation (966_969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels // J. Bone Miner. Res. 2007. V. 22. N 6. P. 938 - 946.
21. Whyte M.P., Mumm S. Heritable disorders of the RANKL/OPG/RANK signalingpathway // J. Musculoskel. Neuronal Interact. 2004. V. 4. № 3. P. 254 - 267.
22. Whyte M.P., Totty W.G., Novack D.V., Zhang X., Wenkert D., Mumm S. Camurati-engelmann disease: unique variant featuring a novel mutation in TGFβ1 encoding transforming growth factor beta 1 and a missense change in TNFSF11 encoding RANK ligand // J. Bone Miner. Res. 2011. V. 26. № 5. P. 920 - 933.
23. Xiong J., Onal M., Jilka R.L., Weinstein R.S., Manolagas S.C., O'Brien C.A. Matrix-embedded cells control osteoclast formation // Nat. Med. 2011. V. 17. P. 1235 - 1241.
24. Osako M.K., Nakagami H., Koibuchi N. et al. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification // Circ. Res. 2010. V. 107. Suppl. 4. P. 466 - 475.
25. Demer L.L., Tintut J. Mechanisms linking osteoporosis with cardiovascular calcification // Curr. Osteopor. Rep. 2009. V. 7. Suppl. 2. P. 42 - 46.
26. Sage A.P., Tintut J., Demer L.L. Regulatory mechanisms in vascular calcification // Nat. Rev. Cardiol. 2010. V. 7. Suppl. 9. P. 528 - 536.
27. Caidahl K., Ueland T., Aukrust P. Osteoprotegerin: a biomarker with many faces // Atherosclerosis, Thrombosis Vasc. Biol. 2010. V. 30. Suppl. 9. P. 1684 - 1686.
28. Van Compenhout A., Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis // Atherosclerosis. 2009. V. 204. Suppl. 2. P. 321 - 329.
29. Morony S., Tintut J., Zhang Z. et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in IdIr (-/-) mice // Circulation. 2008. V. 117. Suppl. 3. P. 411 - 420.
30. Fili S., Karalaki M., Schaller B. Therapeutic implications of osteoprotegerin // Cancer Cell Int. 2009. V. 9. Suppl. 1. P. 26.
31. Peng Bai, Yongchang Sun, Jianmin Jin, Jia Hou, Ran Li, Qing Zhang, Yang Wang. Disturbance of the OPG/RANK/RANKL Pathway and Systemic Inflammation in COPD Patients With Emphysema and Osteoporosis // Respirat. Res. 2011. V. 16. № 12. P 157.
32. Shimamura M., Nakagami H., Osako M.K., Kurinami H., Wakayama K., Koriyama H., Morishita R. Role of OPG/RANKL/RANK System in Ischemic Brain in Mice // Stroke. 2014. 45.
33. Bhatia P., Sanders M.M., Hansen M.F. Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma // Clin. Cancer Res. 2005. V. 11. P. 162 - 165.
34. Santini D., Schiavon G., Vincenzi B., Gaeta L., Pantano F. et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients // PLoS ONE. 2011. V. 6. № 4.
35. Chen G., Sircar K., Aprikian A., Potti A., Goltzman D. et al. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation // Cancer. 2006. V. 107. P. 289 - 298.
36. Farrugia A.N., Atkins G.J., To L.B., Pan B., Horvath N. et al. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo // Cancer Res. 2003. V. 63. P. 5438 ? 5445.
37. Huang L., Xu J., Wood D.J., Zheng M.H. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation // Am. J. Pathol. 2000. V. 156. P. 761 - 767. doi: 10.1016/S0002-9440(10)64942-5.
38. Huang L., Cheng Y.Y., Chow L.T., Zheng M.H., Kumta S.M. Receptor activator of NF-kappaB ligand (RANKL) is expressed in chondroblastoma: possible involvement in osteoclastic giant cell recruitment // Mol. Pathol. 2003. V. 56. P. 116 - 120. doi: 10.1136/mp.56.2.116.
39. Tada T., Jimi E., Okamoto M., Ozeki S., Okabe K. Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts // Int. J. Cancer. 2005. V. 116. P. 253 - 262.
40. Fiumara P., Snell V., Li Y., Mukhopadhyay A., Younes M. et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines // Blood. 2001. V. 98. P. 2784 - 2790.
41. Kitazawa S., Kitazawa R. RANK ligand is a prerequisite for cancer-associated osteolytic lesions // J. Pathol. 2002. V. 198. P. 228 - 236.
42. Whang P.G., Schwarz E.M., Gamradt S.C., Dougall W.C., Lieberman J.R. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone // J. Orthop. Res. 2005. V. 23. P. 1475 - 1483.
43. Zhang D., Schwarz E.M., Rosier R.N., Zuscik M.J., Puzas J.E. et al. ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development // J. Bone Miner. Res. 2003. V. 18. P. 1593 - 1604.
44. Sordillo E.M., Pearse R.N. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma // Cancer. 2003. V. 97. P. 802 - 812.
45. Karapanagiotou E.M., Terpos E., Dilana K.D., Alamara C., Gkiozos I. et al. Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients // Med. Oncol. 2010. V. 27. P. 332 - 338
46. Mikami S., Katsube K., Oya M., Ishida M., Kosaka T. et al. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas // J. Pathol. 2009. V. 218. P. 530 - 539.
47. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities // Nat. Rev. Cancer. 2002. V. 2. P. 584 - 593.
48. Zhang Q., Guo R., Lu Y., Zhao L., Zhou Q., Schwarz E.M. VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism // J. Biol. Chem. 2008. V. 283. P. 13491 - 13499.
49. Roodman G.D., Dougall W.C. RANK ligand as a therapeutic target for bone metastases and multiple myeloma // Cancer Treat. Rev. 2008. V. 34. P. 92 - 101.
50. Totsuka T., Kanai T., Nemoto Y., Tomita T., Okamoto R., Tsuchiya K. et al. RANK-RANKL signaling pathway is critically involved in the function of CD4+CD25+ regulatory T cells in chronic colitis // J. Immunol. 2009. V. 182. P. 6079 ? 6087.
51. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities // Nat. Rev. Cancer. 2002. V. 2. P. 584 - 593.
52. Zhau H.E., Odero-Marah V., Lue H.W., Nomura T., Wang R., Chu G. et al. Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model // Clin. Exp. Metastasis. 2008. V. 25. P. 601 - 610.
53. Buijs J.T., Kuijpers C.C., van der Pluijm G. Targeted therapy options for treatment of bone metastases; beyond bisphosphonates // Curr. Pharm. Des. 2010. V. 16. P. 3015 - 3027.
54. Mikami S., Katsube K., Oya M., Ishida M., Kosaka T., Mizuno R. et al. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas // J. Pathol. 2009. V. 218. P. 530 - 539.
55. Roodman G.D., Dougall W.C. RANK ligand as a therapeutic target for bone metastases and multiple myeloma // Cancer Treat. Rev. 2008. V. 34. P. 92 - 101.
56. Li X., Liao J., Park S.I., Koh A.J., Sadler W.D., Pienta K.J. et al. Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone // Bone. 2011. V. 48. P. 1354 - 1361.
57. Miller R.E., Roudier M., Jones J., Armstrong A., Canon J., Dougall W.C. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis // Mol. Cancer Ther. 2008. V. 7. P. 2160 - 2169.
58. Canon J., Bryant R., Roudier M., Coxon A., Dougall W. RANKL inhibition plus tamoxifen blocks ER+ breast tumor growth in bone metastases and prevents tumor-induced bone loss. In: Proceedings of the IXth International Meeting on Cancer Induced Bone Disease; 2009 Oct 28-31.
59. Canon J., Bryant R., Roudier M., Osgood T., Jones J., Miller R. et al. Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis // Bone. 2010. V. 46. P. 1613 - 1619.
60. Holland P.M., Miller R., Jones J., Douangpanya H., Piasecki J., Roudier M. et al. Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis // Cancer Biol. Ther. 2010. V. 9. P. 539 - 550.
61. Gonzalez-Suarez E., Jacob A.P., Jones J., Miller R., Roudier-Meyer M.P., Erwert R. et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis // Nature. 2010. V. 468. P. 103 - 107.
62. Tan W., Zhang W., Strasner A., Grivennikov S., Cheng J.Q., Hoffman R.M. et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signaling // Nature. 2011. V. 470. P. 548 - 553.
63. Kostenuik P.J., Nguyen H.Q., McCabe J., Warmington K.S., Kurahara C., Sun N. et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL // J. Bone. Miner. Res. 2009. V. 24. P. 182 - 195.
64. van de Wetering de Rooij J., Lyssens C., ten Holder S., D'Artois J., Weeke-Klimp A., Ulrichts H. et al. Safety, pharmacokinetics and efficacy of anti-RANKL nanobody ALX-0141 in healthy postmenopausal women // Ann. Rheum. Dis. 2011. V. 70. Suppl. 3. P. 136.
65. Clinical Trials. gov. Bethesda (MD): NIH. Single ascending-dose study to characterize the safety, pharmacokinetics, and pharmacodynamics of CEP-37251 in healthy postmenopausal women. 2010. Available from: http: // clinicaltrials.gov/show/NCT01159873.
66. Baron R., Ferrari S., Russell R.G. Denosumab and bisphosphonates: different mechanisms of action and effects // Bone. 2011. V. 48. P. 677 - 692.
67. Stopeck A.T., Lipton A., Body J.J., Steger G.G., Tonkin K., de Boer R.H. et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study // J. Clin. Oncol. 2010. V. 28. P. 5132 - 5139.
68. Fizazi K., Carducci M., Smith M., Damião R., Brown J., Karsh L. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study // Lancet. 2011. V. 377. P. 813 - 822.
69. Henry D.H., Costa L., Goldwasser F., Hirsh V., Hungria V., Prausova J. et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma // J. Clin. Oncol. 2011. V. 29. P. 1125 - 1132.